Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Study.
Monge S, Humphreys J, Nicolay N, Braeye T, Van Evercooren I, Holm Hansen C, Emborg HD, Sacco C, Mateo-Urdiales A, Castilla J, Martínez-Baz I, de Gier B, Hahné S, Meijerink H, Kristoffersen AB, Machado A, Soares P, Nardone A, Bacci S, Kissling E, Nunes B; VEBIS‐EHR Working Group.
Monge S, et al. Among authors: humphreys j.
Influenza Other Respir Viruses. 2024 Apr;18(4):e13292. doi: 10.1111/irv.13292.
Influenza Other Respir Viruses. 2024.
PMID: 38654485
Free PMC article.